Cardiff Oncology to Participate in Two Upcoming Investor Conferences

About this update from Cardiff Oncology, Inc.

[{"type":"image","alt":"Cardiff Oncology, Inc.","displaySize":"","headline":null,"caption":"Cardiff Oncology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/c3438e5d34725b0f8f9b8f7493032b71"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wD6rQtC_HUbA6JNQ3Eac3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c3438e5d34725b0f8f9b8f7493032b71","width":300,"height":89}},"lazy":false},{"type":"text","content":"SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in November 2025.","length":315,"tagName":"p"},{"type":"text","content":"Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1 MeetingsPresenters: Mark Erlander, PhD (CEO) Date: 11/11/2025Time: 9:30 AM ET","length":176,"tagName":"p"},{"type":"text","content":"Stifel 2025 Healthcare ConferenceFormat: Corporate Presentation and 1x1 MeetingsPresenters: Mark Erlander, PhD (CEO)Date: 11/12/2025Time: 9:20 AM ET","length":152,"tagName":"p"},{"type":"text","content":"Interested parties can register for and access the live webcast for the conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.","length":228,"tagName":"p"},{"type":"text","content":"About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to ove...

More updates from Cardiff Oncology, Inc.